8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis
Key Takeaways
- Gastroesophageal Reflux Disease (GERD) is diagnosed clinically by classic pyrosis and regurgitation, but the presence of 'alarm features' (dysphagia, odynophagia, unintentional weight loss, anemia, hematemesis, or new-onset dyspepsia at age ≥60) mandates prompt Esophagogastroduodenoscopy (EGD) to rule out upper gastrointestinal malignancy.
- Barrett's esophagus represents specialized intestinal metaplasia (stratified squamous replaced by columnar epithelium with goblet cells) resulting from chronic acid exposure; surveillance endoscopy is required every 3 to 5 years for non-dysplastic Barrett's, while confirmed dysplasia warrants endoscopic eradication therapy (EET).
- Peptic Ulcer Disease (PUD) is predominantly caused by Helicobacter pylori infection and NSAID use; duodenal ulcers characteristically improve with food/antacids and awaken patients at night (12 to 3 AM), whereas gastric ulcers worsen with food and carry a 3% to 5% risk of underlying gastric adenocarcinoma requiring biopsy and follow-up surveillance EGD in 8 to 12 weeks.
- Diagnostic testing for active H. pylori infection (fecal antigen test or urea breath test) requires holding Proton Pump Inhibitors (PPIs) for at least 2 weeks and antibiotics/bismuth for at least 4 weeks to avoid false-negative results; serologic antibody testing cannot distinguish active from resolved infection.
- First-line treatment for H. pylori is 14-day Bismuth Quadruple Therapy (PPI BID + Bismuth subsalicylate + Metronidazole + Tetracycline) due to widespread clarithromycin resistance; eradication must always be confirmed with a test-of-cure (fecal antigen or breath test) performed ≥4 weeks post-antibiotics and ≥2 weeks off PPI therapy.
Last updated: August 2026
Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis
Upper gastrointestinal complaints represent some of the most frequent reasons for ambulatory visits across the adult and geriatric lifespan. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), board certification demands a nuanced understanding of upper GI pathophysiology, the ability to rapidly distinguish benign acid-peptic disorders from covert upper gastrointestinal malignancies, precise mastery of Helicobacter pylori diagnostic and eradication protocols, and vigilant management of pharmacotherapies such as proton pump inhibitors (PPIs).
1. Gastroesophageal Reflux Disease (GERD)
Pathophysiology & Etiology
GERD is a chronic condition characterized by the retrograde flow of gastric contents into the esophagus, resulting in troublesome symptoms and potential mucosal injury. The primary pathophysiological mechanism is dysfunction of the lower esophageal sphincter (LES).
+-----------------------------------------------------------------------------+
| MECHANISMS OF ESOPHAGEAL REFLUX |
| |
| 1. TRANSIENT LES RELAXATIONS (TLESRs) |
| - Vasovagal reflex triggered by gastric distension (most common cause).|
| |
| 2. HYPOTENSIVE BASELINE LES TONE |
| - Resting pressure < 10 mmHg (normal: 10-30 mmHg). |
| - Exacerbated by: nicotine, ethanol, caffeine, chocolate, peppermint, |
| high-fat meals, CCBs, nitrates, anticholinergics, progesterone. |
| |
| 3. ANATOMICAL DISTORTION (HIATAL HERNIA) |
| - Sliding (Type I, 95%): GE junction migrates into posterior |
| mediastinum, creating a reservoir of acid trapped above diaphragm. |
| - Paraesophageal (Type II-IV): Gastric fundus herniates alongside |
| esophagus; high risk of strangulation, volvulus, and ischemia. |
| |
| 4. IMPAIRED ESOPHAGEAL CLEARANCE & DELAYED GASTRIC EMPTYING |
| - Defective secondary peristalsis and diminished salivary bicarbonate. |
| - Gastroparesis (diabetic or idiopathic) increasing intragastric load. |
+-----------------------------------------------------------------------------+
Clinical Presentation: Typical vs. Extraesophageal (Atypical) Manifestations
| Classification | Symptoms & Physical Findings | Pathophysiological Mechanism |
|---|---|---|
| Typical / Esophageal Symptoms | - Pyrosis (Heartburn): Retrosternal burning sensation radiating toward neck, worsened postprandially and when recumbent.<br>- Regurgitation: Effortless return of sour/bitter gastric juice or unformed food into pharynx.<br>- Water Brash: Sudden hypersecretion of alkaline saliva stimulated by esophagosalivary reflex. | Direct chemical irritation of esophageal sensory nociceptors by hydrochloric acid, pepsin, and bile acids. |
| Atypical / Extraesophageal Symptoms | - Chronic Cough: Often nocturnal, dry, non-productive.<br>- Adult-Onset Asthma: Bronchospasm triggered without atopy.<br>- Laryngitis & Hoarseness: Morning voice changes, chronic throat clearing.<br>- Globus Pharyngeus: Sensation of a lump in throat.<br>- Dental Enamel Erosions: Palatal surfaces of maxillary teeth. | - Micro-aspiration of aerosolized gastric acid into larynx and tracheobronchial tree.<br>- Vagal-mediated esophagobronchial reflex bronchoconstriction. |
Diagnostic Evaluation & Clinical "Alarm Features"
- Empiric Trial: In an adult aged <60 presenting with typical GERD symptoms and NO alarm features, a presumptive clinical diagnosis is established, and an empiric 8-week trial of once-daily PPI therapy is initiated.
- Alarm Features Mandating Immediate EGD:
+-----------------------------------------------------------------------------+
| UPPER GI "ALARM FEATURES" (RED FLAGS) |
| |
| * Age >= 60 with new-onset dyspepsia |
| * Progressive Dysphagia (difficulty swallowing: solids -> liquids) |
| * Odynophagia (painful swallowing -> suggests severe ulceration / pill) |
| * Unintentional Weight Loss (> 5% of body weight) |
| * Evidence of GI Blood Loss: Hematemesis, melena, occult positive stool |
| * Unexplained Iron Deficiency Anemia (IDA) |
| * Persistent or Recurrent Vomiting (protracted emesis) |
| * Palpable Abdominal Mass or Lymphadenopathy (Virchow's node, Sister Mary |
| Joseph nodule) |
| * Family history of upper GI adenocarcinoma in a 1st-degree relative |
| * Persistent symptoms despite 8 weeks of optimized twice-daily PPI therapy|
| |
| ---> CLINICAL ACTION: URGENT ESOPHAGOGASTRODUODENOSCOPY (EGD) WITH BIOPSY |
+-----------------------------------------------------------------------------+
Stepwise Management of GERD
-
Lifestyle & Dietary Modifications (Universal Baseline):
- Weight loss for patients with BMI ≥ 25 kg/m² or central adiposity (single most effective lifestyle intervention).
- Elevation of the head of the bed by 6–8 inches (using bed risers or a therapeutic wedge pillow; extra pillows under the head alone bend the torso and increase intra-abdominal pressure!).
- Avoidance of meals within 2–3 hours of lying recumbent or sleeping.
- Tobacco cessation and alcohol elimination.
- Avoidance of dietary triggers: high-fat meals, chocolate, peppermint, citrus fruits, tomato-based products, coffee, and carbonated beverages.
-
Pharmacotherapy:
- Mild / Intermittent GERD (< 2 episodes/week): Low-dose Histamine-2 Receptor Antagonist (H2RA, e.g., Famotidine 10–20 mg BID) as needed or scheduled, or antacids for immediate symptom relief.
- Frequent / Severe GERD (≥ 2 episodes/week) or Erosive Esophagitis: Standard-dose Proton Pump Inhibitor (PPI, e.g., Omeprazole 20 mg, Pantoprazole 40 mg, Esomeprazole 40 mg) administered 30 to 60 minutes before the first meal of the day for 8 weeks.
- Incomplete Response: Increase to twice-daily PPI dosing (administered 30–60 min before breakfast and 30–60 min before dinner), or switch to an alternative PPI molecule.
- Maintenance / Deprescribing: Once symptoms have fully resolved for 8 weeks, step down to the lowest effective dose or trial off therapy, using on-demand H2RAs unless severe erosive esophagitis (Los Angeles Grade C or D) or Barrett's esophagus is present.
2. Barrett's Esophagus & Esophageal Malignancies
Barrett's Esophagus (BE) is a premalignant condition defined as the replacement of normal stratified squamous epithelium of the distal esophagus by specialized columnar epithelium with goblet cells (intestinal metaplasia), extending ≥ 1 cm proximal to the gastroesophageal junction.
+-----------------------------------------------------------------------------+
| BARRETT'S ESOPHAGUS PATHOGENIC CASCADE |
| |
| Normal Distal Esophagus (Stratified Squamous Epithelium) |
| | |
| v (Chronic Acid/Bile Reflux Exposure) |
| Specialized Intestinal Metaplasia (Columnar with Goblet Cells = BE) |
| | |
| v (Genetic Alterations: TP53, CDKN2A) |
| Low-Grade Dysplasia (LGD) |
| | |
| v |
| High-Grade Dysplasia (HGD) |
| | |
| v |
| INVASIVE ESOPHAGEAL ADENOCARCINOMA (EAC) |
+-----------------------------------------------------------------------------+
Screening Indications for Barrett's Esophagus (ACG Guidelines)
Screening EGD is recommended in men with chronic GERD symptoms (>5 years) and/or frequent symptoms (≥ 1 time/week) PLUS ≥ 2 additional risk factors:
- Male biological sex
- Age ≥ 50 years
- Caucasian race
- Central / visceral obesity (elevated waist-to-hip ratio)
- Current or past history of cigarette smoking
- First-degree relative with Barrett's esophagus or esophageal adenocarcinoma
Surveillance & Management Protocols (ACG / AGA Guidelines)
| Histological Grade | Endoscopic Surveillance Interval | Management Strategy |
|---|---|---|
| Non-Dysplastic Barrett's Esophagus (NDBE) | Surveillance EGD every 3 to 5 years (Seattle 4-quadrant biopsy protocol every 2 cm). | Indefinite standard-dose PPI once daily to reduce neoplastic progression; aggressive lifestyle modifications. |
| Low-Grade Dysplasia (LGD) | Must be confirmed by two expert gastrointestinal pathologists. Surveillance EGD every 6 to 12 months OR Endoscopic Eradication Therapy. | Endoscopic Eradication Therapy (EET) utilizing Radiofrequency Ablation (RFA) is preferred over surveillance to prevent progression to HGD/adenocarcinoma. |
| High-Grade Dysplasia (HGD) | Mandatory expert pathology confirmation. | Endoscopic Eradication Therapy (EET): Endoscopic Mucosal Resection (EMR) for visible nodular lesions followed by Radiofrequency Ablation (RFA) of the entire Barrett's segment. Repeat EGD every 3 months during therapy. |
| Intramucosal Adenocarcinoma | Staging with endoscopic ultrasound (EUS) and CT. | Endoscopic resection (EMR/ESD) + ablation for superficial mucosal invasion (T1a); surgical esophagectomy ± chemoradiation for submucosal invasion (T1b) or deeper. |
Comparison of Esophageal Carcinoma Subtypes
| Feature | Esophageal Adenocarcinoma (EAC) | Esophageal Squamous Cell Carcinoma (ESCC) |
|---|---|---|
| Primary Anatomical Location | Distal 1/3 of esophagus (at or near GE junction). | Proximal to middle 2/3 of esophagus. |
| Primary Risk Factors | Chronic GERD, Barrett's esophagus, central obesity, Caucasian males, tobacco. | Cigarette smoking, heavy alcohol consumption, caustic ingestions, achalasia, hot beverages, Black race. |
| Incidence Trend | Rapidly rising in Western nations. | Stable/declining in North America; dominant globally. |
| Clinical Manifestation | Progressive solid food dysphagia → liquid dysphagia, rapid weight loss, odynophagia. | Progressive solid → liquid dysphagia, odynophagia, weight loss, hoarseness (recurrent laryngeal nerve). |
3. Peptic Ulcer Disease (PUD) & NSAID Gastropathy
Peptic Ulcer Disease is defined as a discrete mucosal break ≥ 5 mm in diameter that penetrates through the muscularis mucosae into the submucosa or muscularis propria of the stomach or duodenum.
+-----------------------------------------------------------------------------+
| GASTRIC vs. DUODENAL ULCER MATRIX |
| |
| FEATURE GASTRIC ULCER (GU) DUODENAL ULCER (DU) |
| ----------------------------------------------------------------------- |
| Peak Age 55 - 70 years 30 - 55 years |
| H. pylori Prevalence 60 - 70% 85 - 95% |
| NSAID Association Very Strong (dominant) Moderate |
| Pain Relation to Food WORSENED immediately RELIEVED by food |
| after eating (postprandial) Pain returns 2-5 hrs |
| after meal |
| Nocturnal Awakening Infrequent CLASSIC (12 AM - 3 AM) |
| (acid secretion drops) (peak unbuffered acid) |
| Weight Trajectory Weight LOSS (fear of food) Normal or Weight GAIN |
| Malignancy Risk 3 - 5% (Malignant risk!) Extremely Rare (<0.1%) |
| EGD Biopsy Rule MANDATORY 4-quadrant Biopsy not required |
| biopsies of edge & base for benign-appearing |
| Surveillance EGD REQUIRED at 8-12 weeks NOT required if |
| to document HEALING asymptomatic |
+-----------------------------------------------------------------------------+
NSAID-Induced Gastroduodenal Injury
NSAIDs non-selectively inhibit Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2):
- COX-1 Inhibition: Depletes mucosal prostaglandins (PGE2 and PGI2), which directly decreases gastric bicarbonate secretion, diminishes protective mucosal mucus production, reduces mucosal microvascular blood flow, and impairs epithelial cell restitution.
- Direct Topical Injury: Acidic NSAID molecules become ionically trapped in neutral gastric epithelial cells, causing direct intracellular mitochondrial toxicity and mucosal sloughing.
+-----------------------------------------------------------------------------+
| RISK STRATIFICATION FOR NSAID GASTROPATHY |
| |
| HIGH-RISK FACTORS: |
| * History of prior complicated peptic ulcer (bleeding, perforation) |
| * Age >= 65 years |
| * High-dose or multiple concurrent NSAID therapy (e.g., NSAID + ASA) |
| * Concurrent systemic Corticosteroid therapy (4-fold risk multiplier) |
| * Concurrent Anticoagulant therapy (warfarin, DOAC) or Antiplatelets |
| * Severe chronic comorbid medical illness (CKD, CAD, Cirrhosis) |
| |
| PREVENTIVE PHARMACOLOGIC STRATEGIES: |
| - Co-prescription of daily standard-dose PPI (drug of choice). |
| - Co-prescription of Misoprostol (200 mcg QID - synthetic PGE1 analog; |
| highly effective but limited by diarrhea and abdominal cramping; |
| ABSOLUTELY CONTRAINDICATED in pregnancy due to abortifacient action). |
| - Substitution with a selective COX-2 inhibitor (Celecoxib) PLUS PPI if |
| very high GI risk (caution: assess cardiovascular risk first!). |
+-----------------------------------------------------------------------------+
4. Helicobacter pylori: Microbiology, Diagnostics & Eradication Protocols
Helicobacter pylori is a microaerophilic, flagellated, Gram-negative spiral bacillus that colonizes the human gastric antrum and body. It synthesizes copious quantities of the enzyme urease, which converts gastric urea into ammonia and carbon dioxide, buffering local hydrochloric acid and creating a hospitable neutral microenvironment that facilitates epithelial invasion, chronic gastritis, ulceration, mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric adenocarcinoma.
+-----------------------------------------------------------------------------+
| H. PYLORI DIAGNOSTIC DECISION MATRIX |
| |
| TEST MODALITY SENS / SPEC ADVANTAGES / CLINICAL RULES |
| ----------------------------------------------------------------------- |
| Stool Antigen Test > 95% / > 95% - Detects ACTIVE infection. |
| (Monoclonal EIA) - Excellent for initial dx & cure. |
| - MUST hold PPI x 2 weeks and |
| Antibiotics/Bismuth x 4 weeks. |
| |
| 13C / 14C Urea > 95% / > 95% - Detects ACTIVE infection via |
| Breath Test (UBT) labeled CO2 in exhaled breath. |
| - Excellent for initial dx & cure. |
| - MUST hold PPI x 2 weeks and |
| Antibiotics/Bismuth x 4 weeks. |
| |
| Endoscopic Rapid > 90% / > 95% - Performed on antral biopsy at |
| Urease (CLOtest) time of EGD. |
| - False negative if recent PPI/abx. |
| |
| Serum IgG Serology ~ 85% / ~ 75% - NOT RECOMMENDED in clinical care. |
| (Antibody) - Remains positive for YEARS after |
| successful eradication. |
| - CANNOT distinguish active from |
| past/cured infection! |
+-----------------------------------------------------------------------------+
Guideline-Directed Eradication Regimens (ACG Guidelines)
Due to nationwide clarithromycin resistance exceeding 15% to 20%, Bismuth Quadruple Therapy for 14 days is the gold-standard, preferred first-line eradication regimen regardless of prior macrolide exposure.
+-----------------------------------------------------------------------------+
| PREFERRED FIRST-LINE: BISMUTH QUADRUPLE THERAPY |
| (DURATION: 14 DAYS) |
| |
| 1. PROTON PUMP INHIBITOR (PPI) |
| - Standard dose BID (e.g., Omeprazole 20 mg BID, Pantoprazole 40 mg |
| BID, or Esomeprazole 40 mg BID) taken 30-60 min before meals. |
| |
| 2. BISMUTH SUBSALICYLATE |
| - 300 mg (two chewable 262 mg tabs) FOUR times daily (with meals/bed). |
| - Counsel: causes benign black darkening of tongue and stool. |
| |
| 3. METRONIDAZOLE |
| - 500 mg THREE or FOUR times daily (TID or QID). |
| - Counsel: strictly avoid alcohol (disulfiram-like reaction). |
| |
| 4. TETRACYCLINE |
| - 500 mg FOUR times daily (QID). |
| - Counsel: photosensitivity, pill-induced esophagitis (take with full |
| glass of water, stay upright), avoid in pregnancy/children. |
+-----------------------------------------------------------------------------+
+-----------------------------------------------------------------------------+
| ALTERNATIVE FIRST-LINE: CLARITHROMYCIN TRIPLE THERAPY |
| (DURATION: 14 DAYS) |
| * ONLY acceptable if local Clarithromycin resistance is known < 15% AND |
| patient has NO prior macrolide exposure for any infection! |
| |
| 1. PPI standard dose BID (e.g., Omeprazole 20 mg BID) |
| 2. Clarithromycin 500 mg BID |
| 3. Amoxicillin 1000 mg BID (OR Metronidazole 500 mg BID if penicillin- |
| allergic) |
+-----------------------------------------------------------------------------+
Mandatory Test-of-Cure Protocol
Eradication testing is mandatory for all patients treated for H. pylori to confirm successful cure, prevent recurrence, and reduce gastric cancer risk.
- Timing Requirements:
- Perform test at least 4 weeks after completion of antibiotic therapy.
- Ensure patient has been off all PPI therapy for at least 2 weeks.
- Acceptable Modalities: Monoclonal stool antigen test, Urea breath test, or repeat endoscopy with biopsy if EGD is indicated for another reason. Never use serology for test-of-cure.
5. Chronic Gastritis & Zollinger-Ellison Syndrome
Types of Chronic Gastritis
- Type A Gastritis (Autoimmune Atrophic Gastritis):
- Primarily involves the gastric Fundus and Body (spares the antrum).
- Autoantibodies directed against parietal cells and intrinsic factor.
- Results in achlorhydria (elevated gastric pH), severe hypergastrinemia (loss of negative feedback on G-cells), and pernicious anemia (Vitamin B12 deficiency due to lack of intrinsic factor). Markedly increases risk of gastric neuroendocrine (carcinoid) tumors and gastric adenocarcinoma.
- Type B Gastritis (Bacterial / H. pylori Gastritis):
- Primarily involves the gastric Antrum (can progress pangastrically).
- Driven by H. pylori colonization and mucosal inflammation.
Zollinger-Ellison Syndrome (ZES / Gastrinoma)
- Etiology: A neuroendocrine tumor (gastrinoma) located in the duodenum or pancreas that hypersecretes uncontrolled gastrin, driving massive gastric acid hypersecretion.
- Clinical Clues: Severe, recurrent, refractory peptic ulcers (often multiple, atypical in location such as the jejunum), severe GERD, chronic secretory diarrhea that improves with high-dose PPIs, and weight loss. ~25% occur in association with Multiple Endocrine Neoplasia Type 1 (MEN1).
- Diagnostic Testing:
- Fasting Serum Gastrin (FSG): Gastrin > 1,000 pg/mL in the presence of gastric acid (pH < 2.0) is diagnostic (patient must be off PPIs for 1–2 weeks).
- Secretin Stimulation Test: Confirmatory test for borderline gastrin levels (110–1,000 pg/mL). In ZES, IV secretin paradoxically increases serum gastrin by > 120 pg/mL (in normal individuals, secretin suppresses gastrin).
- Tumor Localization: Somatostatin receptor scintigraphy (68Ga-DOTATATE PET/CT) or endoscopic ultrasound (EUS).
6. Long-Term Risks & Deprescribing of Proton Pump Inhibitors (PPIs)
While PPIs are safe and highly effective for acute acid suppression, chronic long-term hypochlorhydria is associated with distinct clinical safety concerns in adult and geriatric populations:
+-----------------------------------------------------------------------------+
| CHRONIC PPI ADVERSE EFFECTS |
| |
| 1. MICRONUTRIENT MALABSORPTION |
| - Hypomagnesemia (impaired TRPM6/7 active intestinal transport) |
| -> leads to refractory hypocalcemia, secondary hypokalemia, seizures.|
| - Vitamin B12 Deficiency (impaired acid-peptic cleavage from proteins).|
| - Iron Deficiency Anemia (reduced solubilization of non-heme iron). |
| - Calcium Malabsorption & Osteoporotic Fractures (acid needed for |
| calcium carbonate dissolution; recommend CALCIUM CITRATE for PPI users!).|
| |
| 2. ENTERIC & SYSTEMIC INFECTIONS |
| - Clostridioides difficile-Associated Diarrhea (loss of acid barrier). |
| - Small Intestinal Bacterial Overgrowth (SIBO). |
| - Community-Acquired Pneumonia (micro-aspiration of colonized flora). |
| |
| 3. RENAL PATHOLOGY |
| - Acute Interstitial Nephritis (AIN, allergic/idiosyncratic). |
| - Accelerated progression of Chronic Kidney Disease (CKD). |
+-----------------------------------------------------------------------------+
PPI Deprescribing Protocol
- Evaluate Indication: Lifelong PPI is indicated ONLY for: Barrett's esophagus, severe erosive esophagitis (LA Grade C or D), history of bleeding peptic ulcer requiring chronic antiplatelet/NSAID therapy, and Zollinger-Ellison syndrome.
- Tapering Strategy: For uncomplicated GERD, avoid abrupt cessation due to rebound acid hypersecretion (triggered by elevated gastrin stimulating hypertrophied enterochromaffin-like cells). Taper by halving the daily dose for 2–4 weeks, switching to alternate-day dosing, or substituting on-demand Famotidine 20 mg.
Test Your Knowledge
A 64-year-old male presents to the primary care clinic reporting a 4-month history of worsening postprandial epigastric fullness, retrosternal burning, and difficulty swallowing dense solid foods such as steak and bread. Over the past 6 weeks, he has noticed that solid foods 'get stuck' in his mid-chest, forcing him to drink large volumes of water to pass the bolus. He has experienced an unintentional 12-pound weight loss. He has a 30 pack-year smoking history and takes over-the-counter omeprazole 20 mg daily with minimal relief. Physical examination is unremarkable, with no palpable lymphadenopathy or abdominal masses. Complete blood count reveals a microcytic anemia with Hemoglobin 10.8 g/dL and MCV 74 fL. What is the AGPCNP's most appropriate next step in clinical management?
A
B
C
D
Test Your Knowledge
A 52-year-old female presents to the primary care clinic for evaluation of chronic dyspepsia and dull epigastric aching that consistently worsens 30 minutes after meals. She regularly takes naproxen 500 mg twice daily for severe knee osteoarthritis. An upper endoscopy is performed, revealing a discrete 1.2 cm ulcer in the gastric antrum without active bleeding; 4-quadrant mucosal biopsies are obtained. A rapid urease test performed on the biopsy specimen is negative. What is the most appropriate management plan for this patient's gastric ulcer?
A
B
C
D
Test Your Knowledge
A 46-year-old male completes a 14-day course of Bismuth Quadruple Therapy (omeprazole, bismuth subsalicylate, metronidazole, and tetracycline) for an active duodenal ulcer secondary to Helicobacter pylori infection. He presents to the clinic 10 days after finishing his antibiotic regimen, reporting that his epigastric burning is completely resolved. He is currently continuing omeprazole 20 mg daily. He asks if he can undergo testing today to confirm that the infection is gone. How should the AGPCNP advise this patient regarding the test-of-cure protocol?
A
B
C
D